HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Wella

This article was originally published in The Rose Sheet

Executive Summary

Wella: Gucci Envy generates approximately $52 mil. in sales ($1=DM 1.7286) during the fragrance's first year on the market, the company said. The women's scent, which made its debut in the U.S. in March, is expected to generate about $64 mil. in 1997 sales. Envy boosted revenues for Wella's Cosmetic and Scents division, which rose 5.1% in the nine months ended Sept. 30. Net sales for the company increased 11.2% to roughly $1.74 bil. Excluding the effects of divestitures, sales would have increased 13.4%, the German firm noted. The company exited the salon cosmetics business in September with the management buyout of its Paris-based salon company Rene Garraud S.A. ("The Rose Sheet" Sept. 8, In Brief). On constant exchange rates, sales would have risen 9%. Earnings through nine months jumped 26% to about $61 mil. Hair care product revenues within the Professional division climbed 3.8%, while hair care sales in the Retail division increased 11.5%. Within the Professional division, Woodland Hills, Calif.-based Sebastian experienced a 6%-8% sales increase, driven by European and Latin American markets. The company also acquired 100% of its Dzerzhinsk production facility, a Russian-German joint venture. The facility manufactures approximately 10 mil. units of Wella products a year...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel